Related references
Note: Only part of the references are listed.A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma
Andrew B. Lassman et al.
CLINICAL CANCER RESEARCH (2022)
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
Patrick Y. Wen et al.
LANCET ONCOLOGY (2022)
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors
Benjamin M. Ellingson et al.
NEURO-ONCOLOGY (2022)
Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial
David A. Reardon et al.
CANCER (2021)
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
Lakshmi Nayak et al.
CLINICAL CANCER RESEARCH (2021)
Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma
Benjamin M. Ellingson et al.
CLINICAL CANCER RESEARCH (2021)
Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies
Benjamin M. Ellingson et al.
CANCER JOURNAL (2021)
Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials
Benjamin M. Ellingson et al.
NEURO-ONCOLOGY (2021)
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)
Timothy F. Cloughesy et al.
NEURO-ONCOLOGY (2020)
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon et al.
JAMA ONCOLOGY (2020)
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
Wassim Abida et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)
Gil Awada et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Eric Powers et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma
Jiayi Huang et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Trends in response rate and survival in small-cell lung cancer patients between 1997 and 2017
Mickael Lattuca-Truc et al.
LUNG CANCER (2019)
Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma
Thomas J. Kaley et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
How to perform a meta-analysis with R: a practical tutorial
Sara Balduzzi et al.
EVIDENCE-BASED MENTAL HEALTH (2019)
Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma
Benjamin M. Ellingson et al.
NEURO-ONCOLOGY (2018)
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2018)
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
Antonio Omuro et al.
NEURO-ONCOLOGY (2018)
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
F. Poggio et al.
ANNALS OF ONCOLOGY (2018)
Recurrent Glioblastoma Treated with Recombinant Poliovirus
Annick Desjardins et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma
Rimas V. Lukas et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Longitudinal Patterns in Clinical and Imaging Measurements Predict Residual Survival in Glioblastoma Patients
Nova F. Smedley et al.
SCIENTIFIC REPORTS (2018)
Pancreatic cancer: challenges and opportunities
Huiyun Zhu et al.
BMC MEDICINE (2018)
Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE
Brian M. Alexander et al.
CLINICAL CANCER RESEARCH (2018)
Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single- and multicenter trials
Benjamin M. Ellingson et al.
NEURO-ONCOLOGY (2017)
Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
Benjamin M. Ellingson et al.
NEUROTHERAPEUTICS (2017)
Lomustine and Bevacizumab in Progressive Glioblastoma
Wolfgang Wick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma
Nicholas Brown et al.
PLOS ONE (2016)
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma
Timothy F. Cloughesy et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Walter Taal et al.
LANCET ONCOLOGY (2014)
Giant Cell Tumor of Bone in Childhood: Clinical Aspects and Novel Therapeutic Targets
Noah Federman et al.
PEDIATRIC DRUGS (2014)
U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma
Michael Axelson et al.
CLINICAL CANCER RESEARCH (2013)
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma
Andrew D. Norden et al.
NEURO-ONCOLOGY (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Pancreatic cancer: why is it so hard to treat?
Paul E. Oberstein et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2013)
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality
Roger Stupp et al.
EUROPEAN JOURNAL OF CANCER (2012)
Sunitinib malate for the treatment of renal cell carcinoma
Lori Wood
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Assessment of publication bias, selection bias, and unavailable data in meta-analyses using individual participant data: a database survey
Ikhlaaq Ahmed et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Dissemination and publication of research findings: an updated review of related biases
F. Song et al.
HEALTH TECHNOLOGY ASSESSMENT (2010)
Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
James R. Perry et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Study of Cediranib, an Oral Pan-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide
Gregor Dresemann et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
David A. Reardon et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Conducting Meta-Analyses in R with the metafor Package
Wolfgang Viechtbauer
JOURNAL OF STATISTICAL SOFTWARE (2010)
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study
W. K. Alfred Yung et al.
NEURO-ONCOLOGY (2010)
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis.
Darcy A. Krueger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma
D. A. Reardon et al.
BRITISH JOURNAL OF CANCER (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results
Marta Santisteban et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of imatinib in patients with recurrent gliomas of various histologies: A European organisation for research and treatment of cancer brain tumor group study
Eric Raymond et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma
J. F. de Groot et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme
Shuichi Izumoto et al.
JOURNAL OF NEUROSURGERY (2008)
Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
Kathleen R. Lamborn et al.
NEURO-ONCOLOGY (2008)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Random-effects model for meta-analysis of clinical trials: An update
Rebecca DerSimonian et al.
CONTEMPORARY CLINICAL TRIALS (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma:: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
A. A. Brandes et al.
BRITISH JOURNAL OF CANCER (2006)
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastorna multiforme
DA Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study
E Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Weekly high-dose 5-fluorouracil and folinic acid in metastatic pancreatic carcinoma: a phase II study of the EORTC GastroIntestinal Tract Cancer Cooperative Group
REN Van Rijswijk et al.
EUROPEAN JOURNAL OF CANCER (2004)
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study
MD Prados et al.
NEURO-ONCOLOGY (2004)
Phase II study of Fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American brain tumor consortium study
VK Puduvalli et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer?
TD Shanafelt et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme
MC Chamberlain
JOURNAL OF NEURO-ONCOLOGY (2002)
Systematic reviews in health care - Investigating and dealing with publication and other biases in meta-analysis
JAC Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2001)
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
M Brada et al.
ANNALS OF ONCOLOGY (2001)
PCV chemotherapy for recurrent glioblastoma multiforme
AC Kappelle et al.
NEUROLOGY (2001)
Empirical assessment of effect of publication bias on meta-analyses
AJ Sutton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
WKA Yung et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
